Skip to content

Distress screening in lung cancer.

Distress screening and Quality of life in treatment naive lung cancer attending radiotherapy outpatient department.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2016/02/006635
Enrollment
300
Registered
2016-02-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Lung cancer patients with histological confirmation

Interventions

Intervention1: NIL: NIL

Sponsors

Tata Memorial Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Treatment naïve Lung cancer patients with histological confirmation of Non-small cell lung cancer(NSCLC) or Small cell lung cancer (SCLC)attending outpatient department of Radiation oncology and planned for radiotherapy. 2.Aware of their diagnosis and treatment plan. 3.Consenting to participate in study. 4.Age >18years.

Exclusion criteria

Exclusion criteria: 1 Patients with diagnosed psychiatric illness. 2 Patients on Antidepressants, Mood stabilizing agents, Antipsychotics. 3 Patients with Acute medical illness needing intensive medical treatment.

Design outcomes

Primary

MeasureTime frame
Proportion of Clinically significant distress at base line, first and second follow-up.Timepoint: Proportion of Clinically significant distress at base line, first and second follow-up.

Secondary

MeasureTime frame
1 To evaluate prevalence of significant distress in radically treated Lung cancer patients 2. To evaluate factors for distress using NCCN problem check list. 3. To study QOL in patients treated with radical radiation therapy with or without chemotherapy at baseline. 4. To study the Impact of referral to Psycho-oncology and Palliative care along with definitive treatment in patients with significant distress scores in radically treated patient cohort. 5. To correlate DT scores with QoL.Timepoint: Proportion of Clinically significant distress at base line, first (Three Month) and second (Six Month) follow-up.

Countries

India

Contacts

Public ContactDr Kiran Kumar

Tata Memorial Centre

ksajjan7@gmail.com02224177164

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026